Ironwood Pharmaceuticals_INT buy melinda
Startpreis
15.10.18
/
50%
14,73 ?
Kursziel
22.01.19
16,24 €
Rendite (%)
-24,58 %
Endpreis
22.01.19
11,11 €
Zusammenfassung
Diese Einschätzung wurde am 22.01.19 mit einem Endkurs von 11,11 € beendet. Mit einer Rendite von -24,58 % entwickelte sich die Einschätzung BUY nicht nach Plan. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Ironwood Pharmaceuticals_INT | - | - | - | - |
| iShares Core DAX® | -0,45 % | 2,34 % | 15,95 % | 18,10 % |
| iShares Nasdaq 100 | 0,83 % | 5,02 % | 30,98 % | 56,53 % |
| iShares Nikkei 225® | -0,48 % | 0,55 % | 9,21 % | 5,01 % |
| iShares S&P 500 | -0,35 % | 2,63 % | 26,22 % | 46,70 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Ironwood Pharmaceuticals diskutieren
SecteurRecherche biotechnologique et médicale Agenda 06/11 Publication de résultats
Discovers, develops, and intends to commercialize innovative human medicines
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives.
Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout.
The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives.
Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout.
The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.
Nombre d'employés : 730 personnes.
(Vom Mitglied beendet)
Beendete Einschätzungen von melinda zu Ironwood Pharmaceuticals_INT
Ironwood Pharmaceuticals_INT
Startkurs
Kursziel
Rendite (%)
9,59 ?
08.05.19
08.05.19
11,09 €
19.06.19
19.06.19
15,66 %
19.06.19
19.06.19
Ironwood Pharmaceuticals_INT
Startkurs
Kursziel
Rendite (%)
15,33 ?
21.07.17
21.07.17
18,04 €
26.12.17
26.12.17
-9,88 %
26.12.17
26.12.17
Ironwood Pharmaceuticals_INT
Startkurs
Kursziel
Rendite (%)
8,97 ?
19.06.13
19.06.13
12,00 €
19.12.13
19.12.13
-13,51 %
19.12.13
19.12.13
Ironwood Pharmaceuticals_INT
Startkurs
Kursziel
Rendite (%)
7,53 ?
04.10.10
04.10.10
8,50 €
04.04.11
04.04.11
27,84 %
04.04.11
04.04.11